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A Bayesian model to estimate the cutoff and the clinical utility of a biomarker assay 
 
1. Introduction 1 
 2 
The development of diagnostic tests using biomarkers is now an integral part of the drug discovery 3 
and development process. Biomarkers are used in enrichment to assist in patient selection and in the 4 
design of clinical trials [1]. In the field of oncology, for instance, biomarkers are used to develop tests 5 
aiming to identify and treat those who are more likely to respond and demonstrate a higher therapeutic 6 
benefit. The adaptation of these biomarkers based tests for classification purposes requires the 7 
assessment of the test performance and, perhaps even more importantly, their clinical utility.  8 
 9 
The evaluation of the diagnostic performance of a set of potential biomarkers is usually performed 10 
using Receiver Operating Characteristic (ROC) curves, which plot the true positive rate (sensitivity) 11 
versus the false positive rate (1-specificity) over all possible decision thresholds of the test. This is 12 
helpful in choosing the most discriminating marker or set of markers [2]. After choosing an accurate 13 
marker from a set of markers, an appropriate threshold, or cutoff value, must be determined such that 14 
it correctly classifies patients as required.  15 
 16 
Several strategies exist for selecting a cutoff value. These may be based on numerical results around 17 
the sensitivity and specificity, but may also include criteria based on biological or physiological 18 
information. Thus, optimal thresholds may vary depending on the underlying criteria [3]. Most 19 
commonly, the optimal cutoff is chosen as the one that optimizes a utility function. For example, the 20 
cutoff that maximizes the number of correctly classified patients or the cutoff that minimizes the 21 
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misclassification cost. Because a utility function also requires information about cost or benefit, which 22 
is not always available, the optimal cutoff value is found by using criteria related to ROC curves. 23 
Confidence intervals around the cutoff value are obtained either using the delta method or, most 24 
commonly, by employing bootstrapping, though the coverage probabilities can be far from the desired 25 
level [4]. 26 
 27 
ROC-based methods, however, do not provide information on the diagnostic accuracy for a specific 28 
patient. Particularly in situations where a diagnostic test is used for classification purposes, clinicians 29 
are mainly concerned with the predictive ability of the test, approaching the result of the test from the 30 
direction of the patients. The assessment of correct classifications can be facilitated by the use of 31 
positive and negative predictive values (PPV and NPV, respectively). These predictive values are 32 
functions of the accuracy of the test and the overall prevalence, and can be used to assess the clinical 33 
utility of a diagnostic test for classification purposes.  34 
 35 
Lunceford [5] discussed the estimation of the clinical utility of a biomarker assay in the context of 36 
predictive enrichment studies. The aim of his research was to select a cutoff on a potentially predictive 37 
biomarker that can be used as an enrollment criterion for patient selection. By implementing a 38 
Bayesian approach in estimating clinical utility measures he facilitates cutoff decision making, but 39 
without considering the actual cutoff estimation. 40 
 41 
In this paper, we are interested in estimating the cutoff and the clinical utility of a biomarker, but most 42 
importantly the uncertainty around the estimates of the parameters of interest. We propose a flexible 43 
Bayesian approach that can utilize prior information to estimate the cutoff of a biomarker and its 44 
credible interval. By modelling the probability of response with a step function using predictive 45 
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values, we obtain estimates for the cutoff as well as for the predictive values of the test. Bayesian 46 
analysis allows us to assign probability distributions to our prior beliefs for the parameters of interest 47 
and combine these with the data likelihood to yield a posterior probability distribution representing our 48 
updated belief.  49 
 50 
In section 2, we present the Bayesian model for estimating the cutoff of a (continuous or ordinal) 51 
biomarker for a binary outcome. The different prior specifications for the cutoff that we consider allow 52 
for some robustness of the method. The finite-sample performance of the proposed Bayesian approach 53 
is demonstrated through a series of simulations and compared with alternative frequentist methods like 54 
Maximum Likelihood approach and the PSI index in Section 3. We also present applications of our 55 
method in Section 4 on real data for a continuous biomarker and binary, as well as time-to-event 56 
endpoints. Finally, we conclude with a brief discussion. 57 
 58 
2. Methods 59 
2.1 Bayesian model for estimating the cutoff and its credible interval 60 
 61 
In this section we present a Bayesian model for estimating the posterior distribution of a cut-off value 62 
for a biomarker, as well as its predictive values. Let 𝑋 = (𝑋1, 𝑋2, … , 𝑋𝑛) ∈ ℝ denote the continuous 63 
biomarker measurements for n individuals and assume that X is available to be measured on all 64 
patients. Let 𝑌 = (𝑌1, 𝑌2, … , 𝑌𝑛) denote the binary response variable, where 𝑌𝒊 ∈ {0,1} for all 𝑖 =65 
1, … , 𝑛. is the response indicator (e.g. 𝑌𝑖 = 0 denotes the non-responders and 𝑌𝑖 = 1 the responder 66 
subjects). We do not make assumptions about the distribution of the biomarker 𝑋 and by convention it 67 
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will be assumed that high values of the marker 𝑋 are associated with increased probability of response 68 
to a treatment.  69 
 70 
We assume that the probability of response 𝑝 can be modeled by a step function (Figure 1), in terms of 71 
positive predictive value (PPV) and negative predictive value (NPV) of the biomarker assay. The 72 
Positive Predictive Value (PPV) is defined as the conditional probability of response given a positive 73 
test result, i.e.  𝑃(𝑦 = 1|𝑇+). Conventionally, for potential cutoff 𝑐𝑝 ∈ ℝ, the test is positive, 𝑇+, if 74 
the biomarker exceeds the cutoff, 𝑋 ≥ 𝑐𝑝, and is negative otherwise. Similar statements apply for the 75 
Negative Predictive Value (NPV) which is defined as the conditional probability that an individual is a 76 
non-responder given a negative test result, i.e.  𝑃(𝑌 = 0|𝑇−) = 𝑃(𝑌 = 0|𝑋 ≤ 𝑐𝑝). The model is 77 
specified in the following way: 78 
𝑌|𝑋 ~ 𝐵𝑒𝑟𝑛𝑜𝑢𝑙𝑙𝑖(𝑝) 79 
 80 
  𝑝(𝑥) = 𝑃(𝑌 = 1|𝑋 = 𝑥) =  {   
𝑝1 = 𝑃(𝑌 = 1|𝑋 ≤ 𝑐𝑝),   for 𝑥 ≤ 𝑐𝑝 
 
𝑝2 = 𝑃(𝑌 = 1|𝑋 > 𝑐𝑝),   for 𝑥 > 𝑐𝑝   
               (2.1) 81 
 82 
The 𝑝1=1- NPV expresses the probability of response given X is below the cutoff value 𝑐𝑝 and 83 
𝑝2=PPV expresses the probability of response given that X is greater than 𝑐𝑝. 84 
 85 
[Figure 1 about here] 86 
 87 
Logistic regression can be used for decision making, i.e. to classify a subject as responder or not, only 88 
in conjunction to a probability threshold, i.e. 𝑝 = 0.5 [6]. However, the advantage of using the step 89 
function is that the cutoff is a parameter of the model and therefore a Bayesian approach can be 90 
applied. The strong assumption we make that the probability of response can be modeled by a step 91 
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function is probably not always reflecting the reality. However, it may serve as an approximating 92 
model in cases where there are two populations that have a pronounced difference in the response rate. 93 
It follows from literature on misspecified models [7] ,[8] that even, if the model is misspecified the 94 
estimates of the assumed step function are consistent for the parameter values for which the assumed 95 
model minimizes the distance from the true distribution in terms of Kullback-Leibler (KL) divergence 96 
[9].  97 
 98 
2.1.1 Prior specification  99 
 100 
In a Bayesian setup, the idea is to represent the uncertainty about the parameters by a prior 101 
distribution. Prior information can take into account subjective beliefs about the values of the 102 
parameters of the model. This external information can be historical information from experiments, 103 
experts opinion or literature findings. A Bayesian approach can thus be useful as it allows flexibility 104 
combining the available prior knowledge on test characteristics with new data. Importantly, incorrect 105 
prior information can lead to unreliable posterior estimates, and therefore great attention should be 106 
paid to the choice of the prior. On the other hand, if good prior information is available then the gain is 107 
in the precision of the estimates. 108 
 109 
Here, the parameters 𝑝1, 𝑝2 and the cutoff are assumed to have probability distributions reflecting the 110 
uncertainty in their parameters values. For the probabilities of response 𝑝1 and 𝑝2, we consider 111 
distributions that the support set is the interval (0,1). Furthermore, we require that 𝑝2 > 𝑝1. The 112 
simplest case is to assign uniform priors, i.e. 113 
𝑝1 ~ 𝑈𝑛𝑖𝑓(0,1)  and  𝑝2 ~ 𝑈𝑛𝑖𝑓(𝑝1, 1)             (2.2) 114 




For the cutoff 𝑐𝑝, we can consider an informative prior, if prior information is relevant and an 117 
uninformative prior, when there is no information available, usually expressed by a uniform 118 
distribution. Finally a weighted sum of informative and non-informative priors can be considered to 119 
acknowledge potential prior-data conflict. We propose here a two-component mixture of priors, which 120 
allow for robustness. The first component of the mixture prior is the informative part which expresses 121 
the subjective belief we have and is derived from prior experiments, animal data or literature. Then 122 
second component, is the weakly (or non-) informative part that ensures robustness against potential 123 
prior-data conflict. We characterize a prior distribution as weakly informative if the information that 124 
provides is intentionally weaker than whatever actual prior knowledge is available. 125 
 126 
As discussed by Schmidli et.al [10], since one of the mixture components is usually vague, mixture 127 
priors will often be heavy tailed and therefore robust. Let  𝑔1 be the probability density function (pdf) 128 
of the uninformative component and 𝑔2 the pdf for the informative part. The mixture prior can be 129 
expressed as: 130 
                                             𝑐𝑝 = 𝑤 𝑔1 + (1 − 𝑤) 𝑔2                                         (2.3)     131 
with                𝑤 ~ 𝐵𝑒𝑡𝑎(1,1) 132 
The weight parameter 𝑤 will be updated at each iteration by the Bayesian model as described in 133 
section 3.  134 
 135 
2.1.2. Prior specification for constrained positive predictive value 136 
 137 
In this section, we present the case where the objective is to estimate a cutoff associated with a 138 
targeted clinical utility value by controlling the PPV of the test. For example, we might be interested 139 
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in the posterior distribution of the cutoff expected to yield a PPV between 70% and 100% or a 1-NPV 140 
to be between 0 and 20%. Whether a cutoff that yields a pre-specified predicted value exists would of 141 
course depend on the relationship between the biomarker and the response. The idea is then to 142 
incorporate the restriction on the predictive values via the prior information and require that only 143 
information on the pre-specified domain are acceptable. In that case, the constraints can be controlled 144 
through priors, e.g.  145 
𝑝1 ~ 𝑈𝑛𝑖𝑓(0, 𝑝2)  and  𝑝2 ~ 𝑈𝑛𝑖𝑓(0.7,1) 146 
It is worth noting that even if the parameter is constrained such that the actual desired range is not 147 
achievable e.g. 𝑝2 ∉ (0.7, 1), the method will result in the cut-point that is as close as possible to 148 
achieve this constraint (i.e. the mass of the posterior density is on the lower bound of the constrained 149 
interval) 150 
 151 
2.1.3.  Posterior distribution 152 
 153 
The posterior distribution of interest is formulated as  154 
              𝑓(𝑐𝑝, 𝑝1, 𝑝2|𝑥, 𝑦) ∝ 𝐿(𝑝1, 𝑝2, 𝑐𝑝|𝑥, 𝑦) × 𝑓(𝑝1) × 𝑓(𝑝2) × 𝑓(𝑐𝑝)                  (2.4) 155 
where 𝐿(𝑝1, 𝑝2, 𝑐𝑝|𝑥, 𝑦) is the likelihood function of the data and 𝑓(∙) denotes the density of the prior 156 
and 𝑓(∙ |𝑥, 𝑦) the posterior density of the distribution of the parameters. 157 
 158 
2.1.4. Maximum Likelihood Estimation  159 
 160 
The log likelihood of the model described in section 2.1 is given by 161 
 162 
  𝑙𝑜𝑔 𝐿 = 𝐿(𝑝1, 𝑝2, 𝑐𝑝|𝑥, 𝑦) =  ∑ 𝑦𝑖 𝑙𝑜𝑔(𝑝)
𝑛
𝑖=1 + (1 − 𝑦𝑖) 𝑙𝑜𝑔(1 − 𝑝)  163 
 164 
with p as stated in (2.1) and 𝑛 denotes the total sample size. The log likelihood function becomes  165 
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𝑙𝑜𝑔𝐿 = ∑ 𝑦𝑖 𝑙𝑜𝑔(𝑝1)
𝑛1
𝑖=1
+ (1 − 𝑦𝑖) 𝑙𝑜𝑔(1 − 𝑝1) + ∑ 𝑦𝑖 𝑙𝑜𝑔(𝑝2)
𝑛2
𝑖=1
+ (1 − 𝑦𝑖) 𝑙𝑜𝑔(1 − 𝑝2) 166 
Where 𝑛1, 𝑛2 denote the sample size for the population that has  𝑋 ≤ 𝑐𝑝 and 𝑋 > 𝑐𝑝 respectively. 167 
The maximum likelihood estimates 𝑐?̂?, 𝑝1̂ and 𝑝2̂ are obtained by first minimizing – 𝑙𝑜𝑔𝐿 with respect 168 
to 𝑝1 and 𝑝2, for given 𝑐𝑝 and then maximizing the resulting profile likelihood with respect to 𝑐𝑝. One 169 
can see that 𝑝1̂ and 𝑝2̂ are just the average response rates in the subsamples {𝑥𝑖  ≤ 𝑐?̂?} and {𝑥𝑖 > 𝑐?̂?} 170 
where 𝑥𝑖 are the observed values of 𝑋 (see the appendix for a similar argument for the population 171 
parameters). 172 
 173 
3. Simulation Study 174 
 175 
In this section we examine the bias of the estimated cutoff under different distributional  assumptions 176 
for the biomarker 𝑋 via simulations. We compared the proposed Bayesian method with two frequentist 177 
approaches; the Maximum Likelihood Estimator (MLE) and the Predictive Summary Index (PSI) [11]. 178 
The PSI estimates the optimal cutoff by maximizing the difference in predictive values for all possible 179 
cutoffs 𝑐 and is expressed as 𝑃𝑆𝐼 = max
𝑐
{𝑃𝑃𝑉(𝑐) + 𝑁𝑃𝑉(𝑐) − 1}. The PSI is derived in the target 180 
(patient) population as a measure of the goodness of the predictability in a diagnostic test, thus, is a 181 
more comprehensive measure than the Youden index [12] in a clinical setting. For the latter approach, 182 
the confidence intervals are calculated by the bootstrap method by resampling the data 𝐵 = 500 times, 183 
calculating the 𝑃𝑆𝐼𝑗̂  per sample 𝑗 = 1, … , 𝐵. and then taking 𝛼/2 and 1 − 𝛼/2  quantiles of the 𝑃𝑆𝐼𝑗̂  to 184 
construct a (1 −  𝛼) 100% CI. For the Bayesian approach, the credible intervals are obtained by using 185 
the empirical 𝛼/2 and 1 − 𝛼/2 quantiles of the posterior distribution (quantile method). A level of 186 




We include in our results the Maximum Likelihood Estimator (MLE) of the parameters 𝑝1, 𝑝2, 𝑐𝑝 189 
together with the 95% Confidence Intervals (CI) as a comparison. In general, maximum likelihood 190 
methods do not perform well when parameter estimates are on the boundary of the parameter space 191 
[13], leading to some non-convergence issues. On the other hand, Bayesian inference via MCMC 192 
algorithms permits full posterior inference even in the absence of asymptotic normality [14] and have 193 
no issues with parameter estimates on the boundary. In our simulation we did not anticipate any 194 
optimization issues regarding the optimization with the ML method. 195 
 196 
We simulated 10 000 datasets on which we applied all methods. We also report the coverage 197 
probability and the width of the credible and confidence intervals over the simulation runs. The 198 
analysis for the MLE and PSI estimation was done in R version 3.3.3 [15]. The 10 000 datasets were 199 
generated in R (for the MLE and PSI estimation) and then exported to SAS version 9.4 (SAS Institute 200 
Inc., Cary, NC, USA) (for the Bayesian estimation), such that the analysis was consistent for all the 201 
methods. For the PSI method the R-package “OptimalCutpoints” [16] was used and for the profile 202 
MLE the R-library “bbmle” [17]. 203 
 204 
The posterior computation was done by using Markov Chain Monte Carlo (MCMC). In our analysis 205 
we used the Metropolis-Hastings [18], [19] iterative sampling method to approximate the posterior 206 
distribution and get posterior estimates for the parameters in (2.4). Posterior computation was 207 
conducted using PROC MCMC procedure in SAS. The burn-in consisted of 10 000 iterations, and 50 208 
000 subsequent iterations were used for posterior summaries. Convergence of the MCMC chain was 209 
checked for randomly selected number of iterations, using diagnostic plots and the Gelman-Rubin 210 
convergence statistic as well as visually via trace plots, sample autocorrelations and kernel density 211 




3.1 Simulation Setting 214 
3.1.1 Generating data using a step function and a logistic function 215 
 216 
The true model that was used to generate the binary outcome 𝑦 has one biomarker 𝑋. We consider six 217 
different simulation scenarios, each with 𝑛 = 200,  and 𝑛 = 50. Furthermore, we assumed that the 218 
biomarker 𝑋 follows different distributions as shown in Table 1. Each component of the response 219 
vector 𝑦 is viewed as a realization of a Bernoulli random variable with probability of success 𝑝, i.e. 220 
𝑦|𝑋 ~𝐵𝑒𝑟𝑚𝑜𝑢𝑙𝑙𝑖(𝑝). In scenarios 1-4 and 6 the generating model has response probability 𝑝 221 
expressed as a step function, with 𝑝(𝑋) =  {
𝑝1, 𝑖𝑓 𝑋 ≤ 𝑐𝑝
𝑝2, 𝑖𝑓 𝑋 > 𝑐𝑝
, whereas in scenario 5 the generating 222 
model is a logistic model with probability of response 𝑝 =
𝑒𝑋𝛽
1+𝑒𝑋𝛽
.  223 
 224 
The primary purpose of including scenario 5 is to investigate the behavior of the Bayesian method 225 
(together with the MLE and the PSI method), when the fitted model is divergent from the true 226 
underlying model. For this scenario, the true 𝑐𝑝, 𝑝1 and  𝑝2 are not defined by the data generating 227 
mechanism. In fact, it is known (see e.g. [7],[8]) that the estimated parameters from the Bayesian and 228 
MLE method, are consistent for the ones that minimize the Kullback-Leibler divergence between the 229 
fitted (step) model and the true (logistic) model. We give details on the limiting population parameter 230 
in the Appendix. 231 
 232 
In scenario 4, we explore the case that the biomarker 𝑋 is ordinal. The data were generated in the 233 
following way; Assuming 𝑋~𝑁𝑜𝑟𝑚𝑎𝑙(𝜇 = 7, 𝜎2 = 1) as in scenario 1, we calculate the quartiles of 𝑋 234 
that form the four levels of the ordinal variable (the lowest quartile corresponds to category 𝑋 = 1 and 235 
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the 4th quartile to 𝑋 = 4). Each component of the response  𝑌  is a realization from a Bernoulli random 236 
variable with  𝑝(𝑋) =  {
𝑝1, 𝑖𝑓 𝑋 = 1,2
𝑝2, 𝑖𝑓 𝑋 ≥ 3
 .  237 
 238 
Moreover, we are interested to address the case that the true generating model has two cutoffs and the 239 
fitted model assumes only one cutoff (scenario 6 in Table 1). To simulate data for this scenario, 240 
scenario 6, we assumed that 𝑝(𝑋) = {
𝑝1,             𝑖𝑓 𝑋 ≤ 𝑐𝑝1     
 𝑝2,      𝑖𝑓  𝑐𝑝1 < 𝑋 ≤ 𝑐𝑝2
𝑝3,             𝑖𝑓 𝑋 > 𝑐𝑝2     
. If the data indicate the existence of 241 
two cut-off values, this might indicate the existence of two subgroups with different response 242 
probabilities. For the scenarios 2 and 6, we assumed that the biomarker 𝑋 follows a mixture of two 243 
normal distributions expressed as 𝑋~𝑁𝑜𝑟𝑚𝑎𝑙(𝜇 = 𝜇1 , 𝜎
2 = 𝜎21) + 𝑁𝑜𝑟𝑚𝑎𝑙(𝜇 = 𝜇2 , 𝜎
2 = 𝜎22). 244 
 245 
[Table 1 about here] 246 
 247 
3.2. Simulation Results  248 
 249 
This section describes the simulation results regarding the finite sample properties of the estimators 250 
from the Bayesian method, the PSI index and the ML. In our results, we chose to report the Bayesian 251 
posterior mean, as we consider it an adequate measure to summarize the posterior density and we 252 
found that the cutoffs were generally similar whatever estimate kept from the posterior distribution 253 
among the mode, median or mean. In Table 2 and Table 3 we report the Bias of estimators for 𝑐𝑝 254 
(Table 2), 𝑝1, 𝑝2 (Table 3) for scenarios 1-4 based on 10 000 simulation runs. Coverage probability 255 




For the Bayesian method, we also report results for four different prior specifications. The first, the 258 
naïve case, corresponds to a uniform prior (UP) in the interval of the range of the biomarker 259 
measurements. Note here that with a uniform prior, it is well known [20] that, the Bayesian posterior 260 
mode corresponds to the ML estimator. Other priors we considered are a perfect informative prior 261 
(denoted as IPP), an imperfect informative prior (denoted as IPN) and two mixture priors (MixP and 262 
MixN) each with two components; a weighted sum of a uniform and informative prior (UP+IPP) and a 263 
uniform and imperfect informative prior (UP+IPN) respectively. More specifically, for the IPP prior, 264 
we assume a distribution for which the true cutoff lies in an interval of high probability, whereas for 265 
the IPN prior the true cutoff lies in one of the tails of the distribution. An illustration of the IPP and 266 
IPN priors used for scenario 1 can be found in Figure 2. Obviously, when the prior does not include 267 
the true value of the cutoff, then the posterior estimates are expected to be biased for finite sample 268 
sizes. The priors for 𝑝1, 𝑝2 were taken as uniform distributions as given by (2.2). 269 
 270 
[Figure 2 about here] 271 
 272 
Regarding the estimation of the cutoff 𝑐𝑝, in scenarios 1-4, results in Table 2 show that estimators 273 
using all three methods behave similarly in terms of bias, resulting in nearly unbiased estimators. The 274 
Bayesian method gives a much better coverage than the MLE and PSI methods for the scenarios where 275 
the marker is continuous (Table 4). For the PSI method in scenarios 1 and 3, the bias of the estimate of 276 
𝑐𝑝 is far too high in absolute terms (see Table 2). Additionally, the coverage of the bootstrapped 277 
confidence interval is far from the nominal level and the interval width is much wider compared to the 278 
other methods. The Bayesian method performs either the same or better compared to MLE and PSI in 279 




For all priors that we considered, the resulting estimators are on average unbiased for both 𝑛 = 200 282 
and 𝑛 = 50. As expected, with the robust mixture prior and the informative prior, estimates have the 283 
smallest bias on average. The IPP prior gives a smaller interval width with the mixture prior second. 284 
Moreover, with the IPP prior we get more precise estimates while obtaining the same or better 285 
coverage compared to the other prior specifications. 286 
 287 
[Table 2 about here] 288 
[Table 3 about here] 289 
 290 
To see how the prior affects the estimation, we calculate the absolute difference between the estimated 291 
and true value of the cutoff over the simulation runs and we present the results for the Bayesian 292 
method for scenario 1 for all different prior specifications as shown in Figure A.1 in the Appendix. In 293 
Figure A.1, we see that the absolute difference between the estimate and the true value of 𝑐𝑝 was on 294 
average below 10%. As for the predictive values, we discuss our findings for 𝑛 = 200 and show the 295 
results for the estimate of the cutoff. Detailed figures for the predictive values for 𝑛 = 50 can be found 296 
in Table A.1 and Table A.2 in the Appendix.  297 
 298 
As shown in Table 3 and Table 5, all methods performed well with good coverage and very small bias 299 
for both 𝑝1 and 𝑝2. The bias of the estimates for the predictive values 𝑝1 and 𝑝2, was always below 1% 300 
for all scenarios. Coverage probabilities for the credible intervals reach the nominal value for the 301 
Bayesian and the ML method but is not always the case for the estimation of 𝑝2 when using the PSI 302 
index as seen, for example, in scenario 1 and scenario 3, where the coverage probability for the PSI 303 
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method is far from the nominal (Table 5). The length of the credible interval (for the Bayesian 304 
method) was similar to the confidence interval for the MLE and always narrower compared to PSI. 305 
 306 
[Table 4 about here] 307 
[Table 5 about here] 308 
 309 
For scenario 5 where the true model is generated assuming a logistic response curve, we estimated the 310 
cutoff and the corresponding probabilities of response by applying the Bayesian method as well as the 311 
MLE and the PSI approaches. In that case, the true cutoff is not directly defined by the data generating 312 
mechanism. However, the population parameters are defined by minimizing the KL divergence 313 
between the true (logistic) and the assumed (step) model as discussed in section 2.1 and more detailed 314 
in the Appendix. The results of the distribution of the estimates of the parameters for scenario 5 for the 315 
three methods are shown in boxplots in Figure 3. 316 
 317 
In this scenario, the Bayesian estimates are more consistent and have a smaller variability compared to 318 
the MLE and the PSI method. As can be seen from the boxplots, the ML and the PSI methods result in 319 
heavy tailed distributions for all the parameters and especially for the estimate of the cutoff. The 320 
estimates concerning the cutoff and the predicted values obtained with the PSI method, differ 321 
significantly as compared to the other two methods. This is partially due to the fact that the PSI 322 
optimizes a different utility function than the Bayesian and the ML approach. While the Bayesian and 323 
the ML methods use the likelihood as an objective function, the PSI method seeks to maximize the 324 
difference between predictive values (PPV- (1-NPV)) 325 
 326 




For scenario 6, the generating model assumes that there exist two cutoff values and three response 329 
probabilities 𝑝1, 𝑝2, 𝑝3 respectively. The Bayesian model we fit to estimate the cutoff and the 330 
corresponding predictive values, assumes that there is only one cutoff value. For simplicity we used an 331 
UP prior for the Bayesian method. The results of the fitted model are shown in Figure 4. Focusing on 332 
the estimate of 𝑐𝑝, we analyzed the results in more detail. We checked whether the obtained posterior 333 
distribution was bimodal, and if so, we reported the two modes. To check for bimodality, i.e. if the 334 
posterior density function has two peaks, we used the Hartigan’s dip test for unimodality [21]. A p-335 
value less than 0.05 is taken to indicate non-unimodality (it means at least bimodality). 336 
 337 
[Figure 4 about here] 338 
 339 
Figure 5 shows the distribution of the estimated cutoffs when posterior density is judged to be 340 
unimodal (5 733 out of 10 000 simulations) and when it is found to be a bimodal posterior distribution 341 
(4 267 out of 10 000 simulations). Looking across all simulations we see that the cutoff is somewhere 342 
between the two true cutoffs. When only a single mode is identified there is a clear tendency to be 343 
close to the second true cutoff 𝑐𝑝2 = 10. When two modes are found, the underlying two true cutoffs 344 
are estimated reasonably well despite the model misspecification.  345 
 346 
[Figure 5 about here] 347 
 348 
 349 
4. Application 350 
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4.1. The prostate cancer data 351 
 352 
We consider the prostate specific antigen (PSA) study of 12 000 men aged 50–65, which was a 353 
randomized study with a beta-carotene group as the treatment group vs. a placebo group. A substudy 354 
reported by Etzioni et al. [22] analyzed serum levels of total PSA (on the log scale) for 683 subjects. 355 
The dataset is described in [2] and [23] where you can find additional details about the study, which 356 
was analyzed from a non-Bayesian perspective. The primary scientific question under investigation 357 
was whether PSA could be used to diagnose prostate cancer, and was found that the total PSA is a 358 
significant predictor of the occurrence of cancer with fairly good accuracy. Albeit the good diagnostic 359 
ability of the marker PSA, we are interested in estimating a cutoff that takes into account the clinical 360 
benefit of this marker. 361 
 362 
In this paper, we considered response to a treatment as the outcome of interest but the method can be 363 
used also when we refer to diagnostic tests, where the outcome is presence of disease or not. We 364 
analyzed the data described above by applying our Bayesian method to estimate the cutoff related with 365 
disease rates. Probabilistic statements are derived for the optimal cutoff as well as the predictive 366 
values of the marker (logPSA). We assume a uniform prior for the cutoff in the interval (0,100) and 367 
priors for the predictive values defined as in (2.2). We also report the ML estimator and the PSI index.  368 
 369 
Figure 6 shows the posterior distributions for the cutoff (left panel) and the predictive values 𝑝1 and 𝑝2 370 
(middle and right panels respectively). The MLE of the cutoff was found equal to 3.65 with 95% CI 371 
(3.62-3.69), while the posterior median was 3.66 with 95% credible interval (2.44-3.95). The PSI 372 
index which, we remind that maximizes a different objective function, estimates the optimal cutoff to 373 
be 37.66 with 95% bootstrapped CI (7.90-43.30). At that cut-off the PPV and 1-NPV was equal to 1 374 
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and 0.32 respectively. The Bayesian posterior mean for 𝑝1 and 𝑝2 were found equal to 0.17 with 95% 375 
credible interval (0.13-0.22) and 0.73 with 95% credible interval (0.61-0.79) respectively. The MLE 376 
for 𝑝1was 0.18 with 95% confidence interval (0.15-0.21) and for 𝑝2 was 0.75 with 95% confidence 377 
interval (0.68-0.81). 378 
 379 
[Figure 6 about here] 380 
 381 
4.2. Application on survival data: Weibull model for melanoma data 382 
 383 
To illustrate that the proposed approach is useful for more complex settings we consider identifying 384 
the appropriate cutoff for a time to event endpoint. For the following applications on time to event 385 
data, we assume the following let 𝑇𝑖 denote the event time for subject 𝑖. Due to censoring, instead of 386 
observing 𝑇𝑖, we observe the bivariate vector (𝑚𝑖𝑛(𝑇𝑖, 𝐶𝑖),  ∆𝑖) where ∆𝑖= 𝐼(𝑇𝑖 ≤ 𝐶𝑖) with 𝐼 the 387 
indicator function and 𝐶𝑖 is the censoring time. 388 
 389 
The data used are the melanoma dataset available from the R package timereg [24]. The data consist 390 
of measurements made on patients with malignant melanoma and patients with a thick tumor are 391 
thought to have an increased chance of death from melanoma, thus the objective is to estimate a cut-392 
off value on (the log scale of) the tumor size such that the patients below and above the cutoff have a 393 
pronounced difference in their hazard rates. We run the analysis using the R package MHadaptive [25] 394 





To set up the model in the survival setting, the thickness of the tumor on the log scale is denoted by 𝑋,  398 
𝑇 denotes time to death and is assumed to have a Weibull distribution with shape parameter 𝑟 and 399 
scale parameter 𝜆. The assumption is that, based on the thickness of the tumor, we can estimate a 400 
cutoff 𝑐𝑝 such that the two groups defined by 𝑐𝑝, have different hazard functions. Therefore, the shape 401 
and scale parameter for the patients that thickness of their tumor is below 𝑐𝑝 is 𝑟1 and 𝜆1 respectively 402 
and accordingly, 𝑟2 and 𝜆2 for those patients with 𝑋 > 𝑐𝑝.  403 
  𝑇|𝑋~ 𝑊𝑒𝑖𝑏𝑢𝑙𝑙(𝑟, 𝜆)  with   𝑟 = {
𝑟1,    𝑖𝑓 𝑋 ≤ 𝑐𝑝
𝑟2,   𝑖𝑓 𝑋 > 𝑐𝑝
  and    𝜆 = {
𝜆1,    𝑖𝑓 𝑋 ≤ 𝑐𝑝
𝜆2,   𝑖𝑓 𝑋 > 𝑐𝑝
 404 
 405 
Figure 7 (A) shows the posterior densities for the cutoff, the shape and scale parameters. We took the 406 
medians of the posterior densities as point estimates for each parameter. In Figure 7 (B) we plot the 407 
survival curves, estimated with the Kaplan-Meier estimate, for the patients bellow and above the 408 
posterior cutoff estimate, which was taken as the posterior mean equal to 𝑐?̂? = 5.38  with 95% 409 
credible interval (5.07- 5.86). At the same figure we plot the survival curves for the Weibull model in 410 
dashed lines. As seen from the plot, the survival probability decreases with higher tumor thickness 411 
value. To test whether the survival curves for the patients below and above the estimated cutoff value 412 
differ significantly, we applied the log-rank test which showed that there is a significant difference in 413 
survival (p<<0.05). Figure 7 (C) shows the hazard function for the two groups by plugging in the 414 













)𝑟2−1,    𝑖𝑓 𝑋 > 𝑐𝑝
 , with 𝑟1, 𝜆1, 𝑟2, 𝜆2 taken as the means of the posterior densities. 416 
 417 





5. Discussion  
 419 
To enable targeted therapies and enhance medical decision making, biomarkers are increasingly used 420 
in diagnostic tests. When using quantitative biomarkers for classification purposes, defining a reliable 421 
cutoff value for the biomarker is a critical step in the drug development process, as the patient 422 
selection process in the subsequent development steps may depend on this value. Although 423 
classification probabilities, sensitivity and specificity, are considered more relevant to quantify the 424 
inherent accuracy of the test, predictive values quantify the clinical utility of the test. 425 
 426 
We have proposed a Bayesian method to estimate the cutoff value of a biomarker assay using the 427 
predictive values, and also determine the uncertainty around these estimates. We used a step function, 428 
which serves as an approximate model facilitating classification into two groups that have a 429 
pronounced difference in their response rates. The advantage of using the step function is that the 430 
cutoff and predictive values are parameters of the model. Even in the case that the assumption of a step 431 
function is strong and the model is misspecified, the estimates of the assumed step function are 432 
consistent for the parameter values for which the assumed model minimizes the distance from the true 433 
distribution in terms of Kullback-Leibler divergence [7], [8]. A more careful investigation of this 434 
approach is worth further exploration. 435 
 436 
As mentioned by a referee, one could alternatively use a standard classification algorithm, like for 437 
example logistic regression with a probability threshold of 𝑝 = 0.5. One could also choose 𝑝 such that 438 
the Brier score [26], a measure of accuracy of predictions, is minimized. These methods do not 439 
directly address the goal of population separation with regard to positive and negative predictive 440 
values. Moreover, they do not directly provide credible or confidence intervals for the parameters of 441 
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interest which was one of the major goals of the proposed method. Nevertheless, we have compared 442 
the Bayesian approach with these methods and found that the estimated parameters of 𝑐𝑝 are more 443 
biased compared to the Bayesian estimates. Detailed figures can be found in the Appendix. 444 
 445 
The proposed Bayesian approach allows for the estimation of the distribution of the cutoff for 446 
continuous and ordinal biomarkers and permits probabilistic statements about the cutoff values and, 447 
say, the response rates in the two groups. Together with the potential incorporation of prior 448 
information, this is deemed useful especially in the earlier phases of drug development. Results 449 
suggest that the proposed Bayesian method is very tractable in estimating the parameters of interest, 450 
resulting in point estimators (e.g. posterior mean) that are practically unbiased in all scenarios, for all 451 
prior constellations and sample size assumptions.  452 
 453 
In this article, we presented four different prior specifications, including uninformative, informative, 454 
and mixture priors. In all cases, estimation gave satisfying results. Especially when more accurate 455 
prior information is available, the estimated parameters are nearly unbiased with high precision and 456 
good coverage. We suggest a mixture prior that works well in practice, as it is robust towards potential 457 
prior-data conflict. For a dataset of 𝑛 = 200 observations, the Bayesian approach takes 6.3sec to run 458 
on a windows machine with processor Intel Xeon CPU E7-8867 v3 @ 2.5GHz, compared to 459 
frequentist approaches (MLE 0.15sec and for PSI 3.7sec together with the bootstrapped CI). Although 460 
the computational time for the proposed approach is increased, as is the case for Bayesian methods, is 461 
not prohibitive. 462 
 463 
The approach described in this article can be used as a basis for further investigation. The suggested 464 
method was applied to a single biological marker, but it can be generalized to multiple markers. One 465 
21 
 
way to deal with multiple markers is to estimate a composite score for each patient using a 466 
combination of markers (under some working model, for example, under the logistic model), and then 467 
consider this score as the new marker. Furthermore, it would be of great interest to consider the 468 
generalization of the method to estimate multiple cutoffs that can be used potentially for subgroup 469 
identification. In that case, model selection can be used to decide how many cut-offs (indicating the 470 
number of subgroups) the model can have according to the data. 471 
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